Supixa 2.5mg is an anticoagulant medicine containing apixaban 2.5mg. It belongs to a group of medicines known as direct oral anticoagulants (DOACs).
Apixaban works by blocking Factor Xa, reducing the blood's ability to form harmful clots.
It is prescribed for:
Prevention of blood clots following hip or knee replacement surgery.
Prevention of stroke and systemic embolism in selected adults with non-valvular atrial fibrillation who meet the criteria for the reduced dose.
Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial treatment.
The appropriate dose and duration depend on the condition being treated, kidney function, age and other individual factors.
Supixa should be taken consistently according to the prescribed schedule. Do not stop treatment without medical advice, as this may increase the risk of blood clots.
Uses / Indications
Prevention of blood clots after hip or knee replacement surgery.
Prevention of stroke in eligible patients with non-valvular atrial fibrillation.
Prevention of recurrent DVT.
Prevention of recurrent pulmonary embolism.
How to Use
Take orally exactly as prescribed.
The usual dose for the relevant 2.5mg indications is one tablet twice daily.
Swallow with water, with or without food.
Take doses at approximately 12-hour intervals.
Do not double a dose or discontinue treatment without consulting your healthcare professional.
Precautions & Warnings
Do not use if you have active significant bleeding.
Inform your doctor if you have kidney or liver disease or a history of bleeding disorders.
Avoid combining with other anticoagulants or anti-inflammatory medicines unless advised.
Inform your healthcare professional before surgery or dental procedures.
Do not stop treatment abruptly without medical advice.
Common Side Effects
Easy bruising.
Nosebleeds.
Bleeding gums.
Nausea.
Anaemia.
Skin rash.
Seek urgent medical attention if you experience severe or persistent bleeding, blood in your urine, black stools, vomiting blood or sudden severe headaches.












